ClinicalTrials.gg
CompletedNCT02623699VALOR (Part C)Updated Jul 28, 2023Results posted

An Efficacy, Safety, Tolerability, Pharmacokinetics and Pharmacodynamics Study of BIIB067 (Tofersen) in Adults With Inherited Amyotrophic Lateral Sclerosis (ALS)

A Phase 3 interventional study of Tofersen and Placebo in Amyotrophic Lateral Sclerosis, sponsored by Biogen. Completed at 40 sites in 12 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2023-07-28.

Sponsored by Biogen · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
176
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-16

Among 11 studies in Amyotrophic Lateral Sclerosis by Biogen — 2 open to participants now, 4 under way, 1 of them phase 3. Amyotrophic Lateral Sclerosis · Biogen.

Started
2016
with 1 other
Phase 3
2 of 11
none open now
Registered
2nd of 11
by date

Among the 11 studies in Amyotrophic Lateral Sclerosis by Biogen, this one is one of 2 that started in 2016, is one of 2 in phase 3, and was the 2nd registered.

Amyotrophic Lateral Sclerosis

980 studies on the registry are indexed under Amyotrophic Lateral Sclerosis; 279 are open to participants now.

Browse Amyotrophic Lateral Sclerosis studies →

Open to participants now

2 of the 11 studies in Amyotrophic Lateral Sclerosis by Biogen are open now, in 1 country. Recruiting first, the newest first:

By country, each count listing its studies:

All 2 open studies →

Who these studies take

Of the 193 Amyotrophic Lateral Sclerosis studies recruiting now, 118 (61%) set no upper age limit and 23 (12%) stop at 75 or younger; 15 take children under 18; 55 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 11 studies in Amyotrophic Lateral Sclerosis by Biogen, or all of them as a file.
02

Study summary

The primary objectives of Parts A and B of this study are to evaluate the safety, tolerability, and pharmacokinetics (PK) of ascending doses of tofersen in adults with ALS and a documented superoxide dismutase 1 (SOD1) mutation. The primary objective of Part C of this study is to evaluate the clinical efficacy of tofersen administered to adults with ALS and a confirmed SOD1 mutation.

The secondary objective of Parts A and B of this study is to evaluate the effects of tofersen on levels of total SOD1 protein in the cerebrospinal fluid (CSF). The secondary objectives of Part C are to evaluate the safety, tolerability, pharmacodynamic (PD), and biomarker effects of tofersen.

Read the detailed description

This is a 3-part study to examine the efficacy, safety, tolerability, PK, and PD of tofersen. Part A is the single ascending dose (SAD) component of the study, Part B is the multiple ascending dose (MAD) component of study and Part C is the fixed dose component of the study. Hence, the overall phase of development of the study is 1/2/3.

The study completed on 16 Jul 2021. In total, the study enrolled 176 participants, of which 108 enrolled in Part C.

03

Conditions studied

  • Amyotrophic Lateral Sclerosis

Keywords

  • IONIS-SOD1Rx
  • SOD1
  • ALS
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Eligibility criteria

Key Inclusion Criteria: Part A and B

  • Weakness attributable to ALS and documented SOD1 mutation at Screening Visit 2.
  • A forced vital capacity (FVC) ≥50% of predicted value as adjusted for sex, age, and height (from the sitting position). Participants with stable FVC \<50% but ≥45%, whose FVC has not declined by more than 5% in the last 6 months may be considered for inclusion, at the discretion of the Investigator.
  • If taking riluzole, participant must be on a stable dose for ≥30 days prior to Day 1 and expected to remain at that dose until the final study visit.
  • Medically able to undergo the study procedures, and to adhere to the visit schedule at the time of study entry, as determined by the Investigator.

Key Exclusion Criteria: Part A and B

  • History of or positive test result for .
  • History of, or positive test result at Screening, for virus antibody.
  • Current infection (defined as positive for hepatitis B surface antigen [HBsAg] and/or hepatitis B core antibody [HBcAb]). Participants with immunity to hepatitis B from previous natural infection (defined as negative HBsAg, positive hepatitis B surface antibody immunoglobulin G, and positive HBcAb) or vaccination (defined as positive anti-HBs) are eligible to participate in the study.
  • Treatment with another drug, biological agent, or device within 1 month or 5 half-lives of study agent, whichever is longer. Specifically, no prior treatment with small interfering ribonucleic acid, stem cell therapy, or gene therapy is allowed.
  • Current enrollment in any other interventional study.
  • Current or recent (within 1 month) use, or anticipated need, in the opinion of the Investigator, of copper (II) (diacetyl-bis (N4-methylthiosemicarbazone)) or pyrimethamine.
  • Current or anticipated need, in the opinion of the Investigator, of a diaphragm pacing system (DPS) during the study period.

Key Inclusion Criteria: Part C

  • Weakness attributable to ALS and confirmed SOD1 mutation at Screening Visit.
  • If taking riluzole, participant must be on a stable dose for ≥30 days prior to Day 1 and expected to remain at that dose until the final study visit.
  • If taking edaravone, participant must have initiated edaravone ≥60 days (2 treatment cycles) prior to Day 1 and expected to remain at that dose until the final study visit, unless the Investigator determines that edaravone should be discontinued for medical reasons, in which case it may not be restarted during the study. Edaravone may not be administered on dosing days of this study.
  • Medically able to undergo the study procedures and to adhere to the visit schedule at the time of study entry, as determined by the Investigator.

Key Exclusion Criteria: Part C

  • History of or positive test result for human immunodeficiency virus.
  • Current hepatitis C infection (defined as positive hepatitis C virus [HCV] antibody and detectable HCV ribonucleic acid [RNA]). Participants with positive HCV antibody and undetectable HCV RNA are eligible to participate in the study (United States Centers for Disease Control and Prevention).
  • Current hepatitis B infection (defined as positive for HBsAg and/or anti-HBc). participants with immunity to hepatitis B from previous natural infection (defined as negative HBsAg, positive anti-HBc, and positive anti-HBs) or vaccination (defined as negative HBsAg, negative anti-HBc, and positive anti-HBs) are eligible to participate in the study.
  • Treatment with another investigational drug (including investigational drugs for ALS through compassionate use programs), biological agent, or device within 1 month or 5 half-lives of study agent, whichever is longer. Specifically, no prior treatment with small interfering RNA, stem cell therapy, or gene therapy is allowed.
  • Current enrollment in any other interventional study.
  • Current or recent (within 1 month) use, or anticipated need, in the opinion of the Investigator, of copper (II) (diacetyl-bis(N4-methylthiosemicarbazone)) or pyrimethamine.
  • Current or anticipated need, in the opinion of the Investigator, of a DPS during the study period.

NOTE: Other protocol defined Inclusion/Exclusion criteria may apply.

Terms in these criteria, in plain language(4)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
176 participants (actual)

Study arms

  • Placebo comparator
    Part A-SAD: Combined Placebo

    Participants will be administered tofersen-matching placebo once by intrathecal bolus injection on Day 1 of Cohorts 1, 2, 3, and 4 respectively.

    Drug: Placebo

  • Experimental
    Part A-SAD: Cohort 1: Tofersen 10 mg

    Participants will be administered tofersen 10 mg once by intrathecal bolus injection on Day 1.

    Drug: Tofersen

  • Experimental
    Part A-SAD: Cohort 2: Tofersen 20 mg

    Participants will be administered tofersen 20 mg once by intrathecal bolus injection on Day 1 of Cohort 2 after the safety review of Cohort 1.

    Drug: Tofersen

  • Experimental
    Part A-SAD: Cohort 3: Tofersen 40 mg

    Participants will be administered tofersen 40 mg once by intrathecal bolus injection on Day 1 of Cohort 3 after the safety review of Cohort 2.

    Drug: Tofersen

  • Experimental
    Part A-SAD: Cohort 4: Tofersen 60 mg

    Participants will be administered tofersen 60 mg once by intrathecal bolus injection on Day 1 of Cohort 4 after the safety review of Cohort 3.

    Drug: Tofersen

  • Placebo comparator
    Part B-MAD: Combined Placebo

    Participants will be administered tofersen-matching placebo, 3 loading doses once every 2 weeks on Days 1, 15, 29 and 2 maintenance doses once every 4 weeks on Days 57 and 85 by intrathecal injection.

    Drug: Placebo

  • Experimental
    Part B-MAD: Cohort 5: Tofersen 20 mg

    Participants will be administered tofersen 20 mg, 3 loading doses once every 2 weeks on Days 1, 15, 29 and 2 maintenance doses once every 4 weeks on Days 57 and 85 by intrathecal injection.

    Drug: Tofersen

  • Experimental
    Part B-MAD: Cohort 6: Tofersen 40 mg

    Participants will be administered tofersen 40 mg, 3 loading doses once every 2 weeks on Days 1, 15, 29 and 2 maintenance doses once every 4 weeks on Days 57 and 85 by intrathecal injection after the safety and PK review of Cohort 5.

    Drug: Tofersen

  • Experimental
    Part B-MAD: Cohort 7: Tofersen 60 mg

    Participants will be administered tofersen 60 mg, 3 loading doses once every 2 weeks on Days 1, 15, 29 and 2 maintenance doses once every 4 weeks on Days 57 and 85 by intrathecal injection after the safety, PK review and SOD1 PD review of Cohort 6.

    Drug: Tofersen

  • Experimental
    Part B-MAD: Cohort 8: Tofersen 100 mg

    Participants will be administered tofersen 100 mg, 3 loading doses once every 2 weeks on Days 1, 15, 29 and 2 maintenance doses once every 4 weeks on Days 57 and 85 by intrathecal injection after the safety, PK review and SOD1 PD review of Cohort 7.

    Drug: Tofersen

  • Placebo comparator
    Part C-Pivotal: Placebo

    Participants will be administered tofersen-matching placebo, 3 loading doses administered once every 2 weeks on Days 1, 15, 29 followed by 5 maintenance doses administered once every 4 weeks on Days 57, 85, 113, 141, 169 up to 24 weeks by intrathecal bolus injection.

    Drug: Placebo

  • Experimental
    Part C-Pivotal: Tofersen 100 mg

    Participants will be administered tofersen 100 mg, 3 loading doses administered once every 2 weeks on Days 1, 15, 29 followed by 5 maintenance doses administered once every 4 weeks on Days 57, 85, 113, 141, 169 up to 24 weeks by intrathecal bolus injection.

    Drug: Tofersen

Interventions

  • Administered as specified in the treatment arm.

    Also known as: BIIB067, QALSODY

  • DrugPlacebo

    Administered as specified in the treatment arm.

06

What researchers measure

Primary outcomes

  1. Parts A and B: Number of Participants Experiencing Adverse Events (AEs) and Serious Adverse Events (SAEs)

    An AE is any untoward medical occurrence in a participant or clinical investigation participant administered a pharmaceutical product and that does not necessarily have a causal relationship with this treatment. An AE can therefore be any unfavorable and unintended sign (including an abnormal laboratory finding), symptom, or disease temporally associated with the use of a medicinal (investigational) product, whether or not related to the medicinal (investigational) product. A SAE is any untoward medical occurrence that at any dose results in death, life-threatening event, requires inpatient hospitalization, significant disability/incapacity or congenital anomaly.

    Time frame: Part A: First dose up to Day 63; Part B: First dose up to Day 289

  2. Parts A and B: Number of Participants With Clinically Significant Laboratory Abnormalities

    Clinical laboratory assessments included hematology, chemistry, and urinalysis.

    Time frame: Part A: Up to Day 57; Part B: Up to Day 169

  3. Parts A and B: Number of Participants With Clinically Significant Vital Sign Abnormalities

    The criteria for clinically significant vital sign abnormalities include: Temperature: \>38 degree Celsius (°C) or an increase from baseline of ≥1°C; Pulse: \>120 beats per minute (bpm) or an increase from baseline of \>20 bpm, \<50 bpm or a decrease from baseline of \>20 bpm; Systolic blood pressure (BP): \>180 mmHg or an increase from baseline of \>40 mmHg, \<90 mmHg or a decrease from baseline of \>30 mmHg; Diastolic BP: \>105 mmHg or an increase from baseline of \>30 mmHg, \<50 mmHg or a decrease from baseline of \>20 mmHg.

    Time frame: Part A: Up to Day 57; Part B: Up to Day 169

  4. Parts A and B: Number of Participants With Clinically Significant Physical Examination Abnormalities

    Clinically significant physical examination abnormalities included weight decreased.

    Time frame: Part A: Up to Day 57; Part B: Up to Day 169

  5. Parts A and B: Number of Participants With Clinically Significant Neurological Examination Abnormalities

    Clinically significant neurological examination abnormalities included hyporeflexia.

    Time frame: Part A: Up to Day 57; Part B: Up to Day 169

  6. Parts A and B: Number of Participants With Clinically Significant 12-lead Electrocardiograms (ECGs) Abnormalities

    Time frame: Part A: Up to Day 57; Part B: Up to Day 169

  7. Parts A and B: PK Parameter of BIIB067 in Plasma: Maximum Observed Concentration (Cmax)

    Time frame: Part A: Pre-dose, 1, 2, 4, 6 hrs post-dose on Day 1; Part B: Pre-dose, 1, 2, 4, 6 hrs post-dose on Day 1 and 1, 2, 4, 6 hrs post-dose on Day 85

  8. Parts A and B: PK Parameter of BIIB067 in Plasma: Time to Reach Maximum Observed Concentration (Tmax)

    Time frame: Part A: Pre-dose, 1, 2, 4, 6 hrs post-dose on Day 1; Part B: Pre-dose, 1, 2, 4, 6 hrs post-dose on Day 1 and 1, 2, 4, 6 hrs post-dose on Day 85

  9. Parts A and B: PK Parameter of BIIB067 in Plasma: Area Under the Concentration-Time Curve From Time Zero to 24 Hours (AUC0-24h)

    Time frame: Parts A and B: Pre-dose, 1, 2, 4, 6 hrs post-dose on Day 1

  10. Parts A and B: PK Parameter of BIIB067 in Plasma: Area Under the Concentration-time Curve From Time Zero to Infinity (AUCinf)

    Time frame: Part A: Pre-dose Day 1, Days 29 and 57; Part B: Pre-dose Days 1, 15, 29, 57 and 85; Day 106 and 169

  11. Parts A and B: PK Parameter of BIIB067 in Plasma: Area Under the Concentration-time Curve From Time Zero to the Time of the Last Measurable Concentration (AUClast)

    Time frame: Part A: Pre-dose Day 1, Days 29 and 57; Part B: Pre-dose Days 1, 15, 29, 57 and 85; Day 106 and 169

  12. Parts A and B: PK Parameter of BIIB067 in Plasma: Apparent Terminal Elimination Half-life (t1/2)

    Time frame: Part A: Pre-dose Day 1, Days 29 and 57; Part B: Pre-dose Days 1, 15, 29, 57 and 85; Day 106 and 169

  13. Parts A and B: PK Parameters of BIIB067 in CSF Levels: Terminal Elimination Half-life (t1/2)

    Time frame: Part A: Pre-dose Day 1, Days 29 and 57; Part B: Pre-dose Days 1, 15, 29, 57 and 85; Day 106 and 169

  14. Part C: Change From Baseline in Amyotrophic Lateral Sclerosis Functional Rating Scale-Revised (ALSFRS-R) Total Score at Week 28

    The ALSFRS-R measures 4 functional domains, including respiratory, bulbar function, gross motor skills, and fine motor skills. There are 12 questions, each scored from 0 (no function) to 4 (full function), for a total possible score of 48. Scores decline with disease progression. ALSFRS-R scores calculated at diagnosis can be compared to scores throughout time to determine the speed of progression. Higher scores represent better function, negative change from baseline indicates disease progression.

    Time frame: Baseline, Week 28 (Day 197)

Secondary outcomes

  1. Part B: CSF Levels of Total SOD1 Protein Concentration Ratio to Baseline

    Total CSF SOD1 protein ratio to baseline was calculated.

    Time frame: Day 85

  2. Part C: CSF Levels of Total SOD1 Protein Concentration Ratio to Baseline

    Total CSF SOD1 protein ratio to baseline was calculated and LS Geometric Mean ratio to baseline was reported.

    Time frame: Week 28 (Day 197)

  3. Part C: Neurofilament Light Chain (NfL) Plasma Concentration Ratio to Baseline

    NfL is a biomarker whose concentration was assessed in plasma. Plasma NfL ratio to baseline was calculated.

    Time frame: Baseline, Day 197 (Week 28)

  4. Part C: Change From Baseline in Percent Predicted Slow Vital Capacity (SVC) at Week 28

    Vital capacity was measured by means of an SVC test, administered in the upright position.

    Time frame: Baseline, Week 28 (Day 197)

  5. Part C: Change From Baseline in Handheld Dynamometry (HHD) Megascore as Measured by the HHD Device at Week 28

    Quantitative muscle strength was evaluated using HHD, which tests isometric strength of multiple muscles using standard participant positioning. Sixteen muscle groups were evaluated in both upper and lower extremities. The muscle strength values were normalized to Z scores as (post-baseline measurements - mean)/SD and averaged to provide HHD overall megascore. The overall megascore was created by averaging all eight bilateral measurement Z scores, if no more than 10 (≤ 10) measures are missing. A negative change from baseline indicated decreased muscle strength.

    Time frame: Baseline, Week 28 (Day 197)

  6. Part C: Time to Death or Permanent Ventilation

    Time to Death or Permanent Ventilation is defined as the time to the earliest occurrence of one of the following events that were adjudicated by an independent committee: Death; Permanent ventilation (≥22 hours of mechanical ventilation \[invasive or noninvasive\] per day for ≥21 consecutive days).

    Time frame: Baseline up to Week 28 (Day 197)

  7. Part C: Time to Death

    Time frame: Baseline up to Week 28 (Day 197)

  8. Part C: Number of Participants Experiencing AEs and SAEs

    An AE is any untoward medical occurrence in a participant or clinical investigation participant administered a pharmaceutical product and that does not necessarily have a causal relationship with this treatment. An AE can therefore be any unfavorable and unintended sign (including an abnormal laboratory finding), symptom, or disease temporally associated with the use of a medicinal (investigational) product, whether or not related to the medicinal (investigational) product. A SAE is any untoward medical occurrence that at any dose results in death, life-threatening event, requires inpatient hospitalization, significant disability/incapacity or congenital anomaly.

    Time frame: First dose up to Day 236

07

Results

Posted Jul 28, 2023

Participant flow

Participants were enrolled at the investigative sites in the Belgium, Canada, Denmark, France, Germany, Italy, Japan, United Kingdom, and the United States from 20 January 2016 to 16 July 2021.

Part A (Up to 63 Days)
Participant flow — Part A (Up to 63 Days)
MilestonePart A-SAD: Combined PlaceboPart A-SAD: Cohort 1: BIIB067 10 mgPart A-SAD: Cohort 2: BIIB067 20 mgPart A-SAD: Cohort 3: BIIB067 40 mgPart A-SAD: Cohort 4: BIIB067 60 mgPart B-MAD: Combined PlaceboPart B-MAD: Cohort 5: BIIB067 20 mgPart B-MAD: Cohort 6: BIIB067 40 mgPart B-MAD: Cohort 7: BIIB067 60 mgPart B-MAD: Cohort 8: BIIB067 100 mgPart C-Pivotal: PlaceboPart C-Pivotal: BIIB067 100 mg
Started533360000000
Completed523360000000
Not completed010000000000
Withdrew: Consent withdrawn010000000000
Part B (Up to 289 Days)
Participant flow — Part B (Up to 289 Days)
MilestonePart A-SAD: Combined PlaceboPart A-SAD: Cohort 1: BIIB067 10 mgPart A-SAD: Cohort 2: BIIB067 20 mgPart A-SAD: Cohort 3: BIIB067 40 mgPart A-SAD: Cohort 4: BIIB067 60 mgPart B-MAD: Combined PlaceboPart B-MAD: Cohort 5: BIIB067 20 mgPart B-MAD: Cohort 6: BIIB067 40 mgPart B-MAD: Cohort 7: BIIB067 60 mgPart B-MAD: Cohort 8: BIIB067 100 mgPart C-Pivotal: PlaceboPart C-Pivotal: BIIB067 100 mg
Started000001210991000
Completed00000108981000
Not completed000002201000
Withdrew: Lost to follow-up000000100000
Withdrew: Consent withdrawn000001000000
Withdrew: Death000001101000
Part C (Up to 236 Days)
Participant flow — Part C (Up to 236 Days)
MilestonePart A-SAD: Combined PlaceboPart A-SAD: Cohort 1: BIIB067 10 mgPart A-SAD: Cohort 2: BIIB067 20 mgPart A-SAD: Cohort 3: BIIB067 40 mgPart A-SAD: Cohort 4: BIIB067 60 mgPart B-MAD: Combined PlaceboPart B-MAD: Cohort 5: BIIB067 20 mgPart B-MAD: Cohort 6: BIIB067 40 mgPart B-MAD: Cohort 7: BIIB067 60 mgPart B-MAD: Cohort 8: BIIB067 100 mgPart C-Pivotal: PlaceboPart C-Pivotal: BIIB067 100 mg
Started00000000003672
Completed00000000003364
Not completed000000000038
Withdrew: Adverse event000000000002
Withdrew: Consent withdrawn000000000012
Withdrew: Death000000000001
Withdrew: Disease progression000000000023

Outcome measures

PrimaryParts A and B: Number of Participants Experiencing Adverse Events (AEs) and Serious Adverse Events (SAEs)

An AE is any untoward medical occurrence in a participant or clinical investigation participant administered a pharmaceutical product and that does not necessarily have a causal relationship with this treatment. An AE can therefore be any unfavorable and unintended sign (including an abnormal laboratory finding), symptom, or disease temporally associated with the use of a medicinal (investigational) product, whether or not related to the medicinal (investigational) product. A SAE is any untoward medical occurrence that at any dose results in death, life-threatening event, requires inpatient hospitalization, significant disability/incapacity or congenital anomaly.

Time frame:
Part A: First dose up to Day 63; Part B: First dose up to Day 289
Reported as:
Count of participants · Participants
Parts A and B: Number of Participants Experiencing Adverse Events (AEs) and Serious Adverse Events (SAEs)
ParticipantsPart A-SAD: Combined PlaceboPart A-SAD: Cohort 1: BIIB067 10 mgPart A-SAD: Cohort 2: BIIB067 20 mgPart A-SAD: Cohort 3: BIIB067 40 mgPart A-SAD: Cohort 4: BIIB067 60 mgPart B-MAD: Combined PlaceboPart B-MAD: Cohort 5: BIIB067 20 mgPart B-MAD: Cohort 6: BIIB067 40 mgPart B-MAD: Cohort 7: BIIB067 60 mgPart B-MAD: Cohort 8: BIIB067 100 mg
AEs2233612109910
SAEs0000022120
PrimaryParts A and B: Number of Participants With Clinically Significant Laboratory Abnormalities

Clinical laboratory assessments included hematology, chemistry, and urinalysis.

Time frame:
Part A: Up to Day 57; Part B: Up to Day 169
Reported as:
Count of participants · Participants
Parts A and B: Number of Participants With Clinically Significant Laboratory Abnormalities
ParticipantsPart A-SAD: Combined PlaceboPart A-SAD: Cohort 1: BIIB067 10 mgPart A-SAD: Cohort 2: BIIB067 20 mgPart A-SAD: Cohort 3: BIIB067 40 mgPart A-SAD: Cohort 4: BIIB067 60 mgPart B-MAD: Combined PlaceboPart B-MAD: Cohort 5: BIIB067 20 mgPart B-MAD: Cohort 6: BIIB067 40 mgPart B-MAD: Cohort 7: BIIB067 60 mgPart B-MAD: Cohort 8: BIIB067 100 mg
Pleocytosis0000002100
Eosinophilia0000000001
Blood Phosphorus Decreased0000000010
CSF Protein Increased0000010041
CSF White Blood Cell Count Increased0000000130
CSF White Blood Cell Count Positive0000000001
Gamma-Glutamyltransferase Increased0000001000
Urine Output Decreased0000010000
PrimaryParts A and B: Number of Participants With Clinically Significant Vital Sign Abnormalities

The criteria for clinically significant vital sign abnormalities include: Temperature: \>38 degree Celsius (°C) or an increase from baseline of ≥1°C; Pulse: \>120 beats per minute (bpm) or an increase from baseline of \>20 bpm, \<50 bpm or a decrease from baseline of \>20 bpm; Systolic blood pressure (BP): \>180 mmHg or an increase from baseline of \>40 mmHg, \<90 mmHg or a decrease from baseline of \>30 mmHg; Diastolic BP: \>105 mmHg or an increase from baseline of \>30 mmHg, \<50 mmHg or a decrease from baseline of \>20 mmHg.

Time frame:
Part A: Up to Day 57; Part B: Up to Day 169
Reported as:
Count of participants · Participants
Parts A and B: Number of Participants With Clinically Significant Vital Sign Abnormalities
ParticipantsPart A-SAD: Combined PlaceboPart A-SAD: Cohort 1: BIIB067 10 mgPart A-SAD: Cohort 2: BIIB067 20 mgPart A-SAD: Cohort 3: BIIB067 40 mgPart A-SAD: Cohort 4: BIIB067 60 mgPart B-MAD: Combined PlaceboPart B-MAD: Cohort 5: BIIB067 20 mgPart B-MAD: Cohort 6: BIIB067 40 mgPart B-MAD: Cohort 7: BIIB067 60 mgPart B-MAD: Cohort 8: BIIB067 100 mg
Parts A and B: Number of Participants With Clinically Significant Vital Sign Abnormalities0000000000
PrimaryParts A and B: Number of Participants With Clinically Significant Physical Examination Abnormalities

Clinically significant physical examination abnormalities included weight decreased.

Time frame:
Part A: Up to Day 57; Part B: Up to Day 169
Reported as:
Count of participants · Participants
Parts A and B: Number of Participants With Clinically Significant Physical Examination Abnormalities
ParticipantsPart A-SAD: Combined PlaceboPart A-SAD: Cohort 1: BIIB067 10 mgPart A-SAD: Cohort 2: BIIB067 20 mgPart A-SAD: Cohort 3: BIIB067 40 mgPart A-SAD: Cohort 4: BIIB067 60 mgPart B-MAD: Combined PlaceboPart B-MAD: Cohort 5: BIIB067 20 mgPart B-MAD: Cohort 6: BIIB067 40 mgPart B-MAD: Cohort 7: BIIB067 60 mgPart B-MAD: Cohort 8: BIIB067 100 mg
Parts A and B: Number of Participants With Clinically Significant Physical Examination Abnormalities0000010001
PrimaryParts A and B: Number of Participants With Clinically Significant Neurological Examination Abnormalities

Clinically significant neurological examination abnormalities included hyporeflexia.

Time frame:
Part A: Up to Day 57; Part B: Up to Day 169
Reported as:
Count of participants · Participants
Parts A and B: Number of Participants With Clinically Significant Neurological Examination Abnormalities
ParticipantsPart A-SAD: Combined PlaceboPart A-SAD: Cohort 1: BIIB067 10 mgPart A-SAD: Cohort 2: BIIB067 20 mgPart A-SAD: Cohort 3: BIIB067 40 mgPart A-SAD: Cohort 4: BIIB067 60 mgPart B-MAD: Combined PlaceboPart B-MAD: Cohort 5: BIIB067 20 mgPart B-MAD: Cohort 6: BIIB067 40 mgPart B-MAD: Cohort 7: BIIB067 60 mgPart B-MAD: Cohort 8: BIIB067 100 mg
Parts A and B: Number of Participants With Clinically Significant Neurological Examination Abnormalities0000100000
PrimaryParts A and B: Number of Participants With Clinically Significant 12-lead Electrocardiograms (ECGs) Abnormalities
Time frame:
Part A: Up to Day 57; Part B: Up to Day 169
Reported as:
Count of participants · Participants
Parts A and B: Number of Participants With Clinically Significant 12-lead Electrocardiograms (ECGs) Abnormalities
ParticipantsPart A-SAD: Combined PlaceboPart A-SAD: Cohort 1: BIIB067 10 mgPart A-SAD: Cohort 2: BIIB067 20 mgPart A-SAD: Cohort 3: BIIB067 40 mgPart A-SAD: Cohort 4: BIIB067 60 mgPart B-MAD: Combined PlaceboPart B-MAD: Cohort 5: BIIB067 20 mgPart B-MAD: Cohort 6: BIIB067 40 mgPart B-MAD: Cohort 7: BIIB067 60 mgPart B-MAD: Cohort 8: BIIB067 100 mg
Maximum Increase From Baseline QTcF > 30 to 60 ms0000031223
Maximum Post-baseline QTcF > 480 to 500 ms0000010000
PrimaryParts A and B: PK Parameter of BIIB067 in Plasma: Maximum Observed Concentration (Cmax)
Time frame:
Part A: Pre-dose, 1, 2, 4, 6 hrs post-dose on Day 1; Part B: Pre-dose, 1, 2, 4, 6 hrs post-dose on Day 1 and 1, 2, 4, 6 hrs post-dose on Day 85
Reported as:
Geometric mean · ng/mL
Parts A and B: PK Parameter of BIIB067 in Plasma: Maximum Observed Concentration (Cmax)
ng/mLPart A-SAD: Cohort 1: BIIB067 10 mgPart A-SAD: Cohort 2: BIIB067 20 mgPart A-SAD: Cohort 3: BIIB067 40 mgPart A-SAD: Cohort 4: BIIB067 60 mgPart B-MAD: Cohort 5: BIIB067 20 mgPart B-MAD: Cohort 6: BIIB067 40 mgPart B-MAD: Cohort 7: BIIB067 60 mgPart B-MAD: Cohort 8: BIIB067 100 mg
Day 164.94 (38.8 to 159.0)75.06 (43.0 to 144.0)202.09 (174.0 to 236.0)529.63 (148.0 to 1450.0)80.75 (20.1 to 393.0)229.41 (26.3 to 948.0)437.28 (128.0 to 1930.0)1031.74 (285.0 to 3530.0)
Day 85————112.74 (29.7 to 203.0)199.69 (93.6 to 537.0)411.00 (74.1 to 1450.0)1181.83 (170.0 to 3990.0)
PrimaryParts A and B: PK Parameter of BIIB067 in Plasma: Time to Reach Maximum Observed Concentration (Tmax)
Time frame:
Part A: Pre-dose, 1, 2, 4, 6 hrs post-dose on Day 1; Part B: Pre-dose, 1, 2, 4, 6 hrs post-dose on Day 1 and 1, 2, 4, 6 hrs post-dose on Day 85
Reported as:
Geometric mean · hours
Parts A and B: PK Parameter of BIIB067 in Plasma: Time to Reach Maximum Observed Concentration (Tmax)
hoursPart A-SAD: Cohort 1: BIIB067 10 mgPart A-SAD: Cohort 2: BIIB067 20 mgPart A-SAD: Cohort 3: BIIB067 40 mgPart A-SAD: Cohort 4: BIIB067 60 mgPart B-MAD: Cohort 5: BIIB067 20 mgPart B-MAD: Cohort 6: BIIB067 40 mgPart B-MAD: Cohort 7: BIIB067 60 mgPart B-MAD: Cohort 8: BIIB067 100 mg
Day 14.58 (4.0 to 6.0)4.16 (2.0 to 6.0)6.00 (6.0 to 6.0)2.70 (2.0 to 6.0)7.01 (2.0 to 24.0)3.68 (1.0 to 6.0)2.44 (1.0 to 6.0)3.67 (1.0 to 24.0)
Day 85————3.93 (2.0 to 6.0)3.97 (1.0 to 6.0)3.12 (1.0 to 6.0)3.82 (1.0 to 6.0)
PrimaryParts A and B: PK Parameter of BIIB067 in Plasma: Area Under the Concentration-Time Curve From Time Zero to 24 Hours (AUC0-24h)
Time frame:
Parts A and B: Pre-dose, 1, 2, 4, 6 hrs post-dose on Day 1
Reported as:
Geometric mean · hour*ng/mL
Parts A and B: PK Parameter of BIIB067 in Plasma: Area Under the Concentration-Time Curve From Time Zero to 24 Hours (AUC0-24h)
hour*ng/mLPart A-SAD: Cohort 1: BIIB067 10 mgPart A-SAD: Cohort 2: BIIB067 20 mgPart A-SAD: Cohort 3: BIIB067 40 mgPart A-SAD: Cohort 4: BIIB067 60 mgPart B-MAD: Cohort 5: BIIB067 20 mgPart B-MAD: Cohort 6: BIIB067 40 mgPart B-MAD: Cohort 7: BIIB067 60 mgPart B-MAD: Cohort 8: BIIB067 100 mg
Parts A and B: PK Parameter of BIIB067 in Plasma: Area Under the Concentration-Time Curve From Time Zero to 24 Hours (AUC0-24h)879.86 (550.8 to 1989.5)1027.18 (879.2 to 1263.2)2873.77 (2347.2 to 3543.4)5196.11 (2410.2 to 10977.3)1009.85 (372.8 to 2192.3)2875.13 (541.1 to 6984.8)4289.16 (1347.6 to 10637.1)11344.47 (4025.5 to 26143.0)
PrimaryParts A and B: PK Parameter of BIIB067 in Plasma: Area Under the Concentration-time Curve From Time Zero to Infinity (AUCinf)
Time frame:
Part A: Pre-dose Day 1, Days 29 and 57; Part B: Pre-dose Days 1, 15, 29, 57 and 85; Day 106 and 169
Reported as:
Mean · hour*ng/mL
Parts A and B: PK Parameter of BIIB067 in Plasma: Area Under the Concentration-time Curve From Time Zero to Infinity (AUCinf)
hour*ng/mLPart A-SAD: Cohort 1: BIIB067 10 mgPart A-SAD: Cohort 2: BIIB067 20 mgPart A-SAD: Cohort 3: BIIB067 40 mgPart A-SAD: Cohort 4: BIIB067 60 mgPart B-MAD: Cohort 5: BIIB067 20 mgPart B-MAD: Cohort 6: BIIB067 40 mgPart B-MAD: Cohort 7: BIIB067 60 mgPart B-MAD: Cohort 8: BIIB067 100 mg
Parts A and B: PK Parameter of BIIB067 in Plasma: Area Under the Concentration-time Curve From Time Zero to Infinity (AUCinf)NA ± NANA ± NANA ± NANA ± NANA ± NANA ± NANA ± NANA ± NA
PrimaryParts A and B: PK Parameter of BIIB067 in Plasma: Area Under the Concentration-time Curve From Time Zero to the Time of the Last Measurable Concentration (AUClast)
Time frame:
Part A: Pre-dose Day 1, Days 29 and 57; Part B: Pre-dose Days 1, 15, 29, 57 and 85; Day 106 and 169
Reported as:
Mean · hour*ng/mL
Parts A and B: PK Parameter of BIIB067 in Plasma: Area Under the Concentration-time Curve From Time Zero to the Time of the Last Measurable Concentration (AUClast)
hour*ng/mLPart A-SAD: Cohort 1: BIIB067 10 mgPart A-SAD: Cohort 2: BIIB067 20 mgPart A-SAD: Cohort 3: BIIB067 40 mgPart A-SAD: Cohort 4: BIIB067 60 mgPart B-MAD: Cohort 5: BIIB067 20 mgPart B-MAD: Cohort 6: BIIB067 40 mgPart B-MAD: Cohort 7: BIIB067 60 mgPart B-MAD: Cohort 8: BIIB067 100 mg
Parts A and B: PK Parameter of BIIB067 in Plasma: Area Under the Concentration-time Curve From Time Zero to the Time of the Last Measurable Concentration (AUClast)NA ± NANA ± NANA ± NANA ± NANA ± NANA ± NANA ± NANA ± NA
PrimaryParts A and B: PK Parameter of BIIB067 in Plasma: Apparent Terminal Elimination Half-life (t1/2)
Time frame:
Part A: Pre-dose Day 1, Days 29 and 57; Part B: Pre-dose Days 1, 15, 29, 57 and 85; Day 106 and 169
Reported as:
Median · hours
Parts A and B: PK Parameter of BIIB067 in Plasma: Apparent Terminal Elimination Half-life (t1/2)
hoursPart A-SAD: Cohort 1: BIIB067 10 mgPart A-SAD: Cohort 2: BIIB067 20 mgPart A-SAD: Cohort 3: BIIB067 40 mgPart A-SAD: Cohort 4: BIIB067 60 mgPart B-MAD: Cohort 5: BIIB067 20 mgPart B-MAD: Cohort 6: BIIB067 40 mgPart B-MAD: Cohort 7: BIIB067 60 mgPart B-MAD: Cohort 8: BIIB067 100 mg
Parts A and B: PK Parameter of BIIB067 in Plasma: Apparent Terminal Elimination Half-life (t1/2)NA (NA to NA)NA (NA to NA)NA (NA to NA)NA (NA to NA)NA (NA to NA)NA (NA to NA)NA (NA to NA)NA (NA to NA)
PrimaryParts A and B: PK Parameters of BIIB067 in CSF Levels: Terminal Elimination Half-life (t1/2)
Time frame:
Part A: Pre-dose Day 1, Days 29 and 57; Part B: Pre-dose Days 1, 15, 29, 57 and 85; Day 106 and 169
Reported as:
Median · hours
Parts A and B: PK Parameters of BIIB067 in CSF Levels: Terminal Elimination Half-life (t1/2)
hoursPart A-SAD: Cohort 1: BIIB067 10 mgPart A-SAD: Cohort 2: BIIB067 20 mgPart A-SAD: Cohort 3: BIIB067 40 mgPart A-SAD: Cohort 4: BIIB067 60 mgPart B-MAD: Cohort 5: BIIB067 20 mgPart B-MAD: Cohort 6: BIIB067 40 mgPart B-MAD: Cohort 7: BIIB067 60 mgPart B-MAD: Cohort 8: BIIB067 100 mg
Parts A and B: PK Parameters of BIIB067 in CSF Levels: Terminal Elimination Half-life (t1/2)NA (NA to NA)NA (NA to NA)NA (NA to NA)NA (NA to NA)NA (NA to NA)NA (NA to NA)NA (NA to NA)NA (NA to NA)
PrimaryPart C: Change From Baseline in Amyotrophic Lateral Sclerosis Functional Rating Scale-Revised (ALSFRS-R) Total Score at Week 28

The ALSFRS-R measures 4 functional domains, including respiratory, bulbar function, gross motor skills, and fine motor skills. There are 12 questions, each scored from 0 (no function) to 4 (full function), for a total possible score of 48. Scores decline with disease progression. ALSFRS-R scores calculated at diagnosis can be compared to scores throughout time to determine the speed of progression. Higher scores represent better function, negative change from baseline indicates disease progression.

Time frame:
Baseline, Week 28 (Day 197)
Reported as:
Least squares mean · score on scale
Part C: Change From Baseline in Amyotrophic Lateral Sclerosis Functional Rating Scale-Revised (ALSFRS-R) Total Score at Week 28
score on scalePart C-Pivotal: PlaceboPart C-Pivotal: BIIB067 100 mg
Part C: Change From Baseline in Amyotrophic Lateral Sclerosis Functional Rating Scale-Revised (ALSFRS-R) Total Score at Week 28-8.1 ± 1.79-7.0 ± 1.42
Statistical analysis
  • Part C-Pivotal: Placebo vs Part C-Pivotal: BIIB067 100 mg · Joint rank · p = = 0.9689 (Joint rank p-value was calculated from ANCOVA model which included treatment as fixed effect, adjusts for covariates: Baseline disease duration since symptom onset, baseline ALSFRS-R total score, and use of riluzole or edaravone.) · Least square (ls) mean difference: 1.2 · 95% CI -3.19 to 5.53ANCOVA model included treatment as a fixed effect, adjusts for the covariates: Baseline disease duration since symptom onset, baseline ALSFRS-R total score, and use of riluzole or edaravone.
SecondaryPart B: CSF Levels of Total SOD1 Protein Concentration Ratio to Baseline

Total CSF SOD1 protein ratio to baseline was calculated.

Time frame:
Day 85
Reported as:
Geometric mean · ratio
Part B: CSF Levels of Total SOD1 Protein Concentration Ratio to Baseline
ratioPart B-MAD: Combined PlaceboPart B-MAD: Cohort 5: BIIB067 20 mgPart B-MAD: Cohort 6: BIIB067 40 mgPart B-MAD: Cohort 7: BIIB067 60 mgPart B-MAD: Cohort 8: BIIB067 100 mg
Part B: CSF Levels of Total SOD1 Protein Concentration Ratio to Baseline0.97 (0.83 to 1.13)0.99 (0.83 to 1.18)0.73 (0.61 to 0.87)0.79 (0.66 to 0.94)0.64 (0.55 to 0.76)
Statistical analysis
  • Part B-MAD: Combined Placebo vs Part B-MAD: Cohort 5: BIIB067 20 mg · Wilcoxon rank sum test · p = < 0.0001 · Difference in ls geometric mean ratio: 0.67 · 95% CI 0.53 to 0.84
  • Part B-MAD: Combined Placebo vs Part B-MAD: Cohort 6: BIIB067 40 mg · Wilcoxon rank sum test · p = =0.0002 · Difference in ls geometric mean ratio: 0.75 · 95% CI 0.60 to 0.95
  • Part B-MAD: Combined Placebo vs Part B-MAD: Cohort 7: BIIB067 60 mg · Wilcoxon rank sum test · p = =0.0641 · Difference in ls geometric mean ratio: 0.81 · 95% CI 0.65 to 1.02
  • Part B-MAD: Combined Placebo vs Part B-MAD: Cohort 8: BIIB067 100 mg · Wilcoxon rank sum test · p = <0.0001 · Difference in ls geometric mean ratio: 0.67 · 95% CI 0.53 to 0.84
SecondaryPart C: CSF Levels of Total SOD1 Protein Concentration Ratio to Baseline

Total CSF SOD1 protein ratio to baseline was calculated and LS Geometric Mean ratio to baseline was reported.

Time frame:
Week 28 (Day 197)
Reported as:
Geometric least squares mean · ratio
Part C: CSF Levels of Total SOD1 Protein Concentration Ratio to Baseline
ratioPart C-Pivotal: PlaceboPart C-Pivotal: BIIB067 100 mg
Part C: CSF Levels of Total SOD1 Protein Concentration Ratio to Baseline1.16 (0.96 to 1.40)0.71 (0.62 to 0.83)
Statistical analysis
  • Part C-Pivotal: Placebo vs Part C-Pivotal: BIIB067 100 mg · ANCOVA · p = < 0.0001 (The analysis was based on ANCOVA model with natural log transformed data. P-value for this secondary outcome measure (OM) is nominal as statistical significance was not met on the primary OM.) · Difference in ls geometric mean ratio: 0.62 · 95% CI 0.49 to 0.78
SecondaryPart C: Neurofilament Light Chain (NfL) Plasma Concentration Ratio to Baseline

NfL is a biomarker whose concentration was assessed in plasma. Plasma NfL ratio to baseline was calculated.

Time frame:
Baseline, Day 197 (Week 28)
Reported as:
Geometric least squares mean · ratio
Part C: Neurofilament Light Chain (NfL) Plasma Concentration Ratio to Baseline
ratioPart C-Pivotal: PlaceboPart C-Pivotal: BIIB067 100 mg
Part C: Neurofilament Light Chain (NfL) Plasma Concentration Ratio to Baseline1.20 (0.94 to 1.52)0.40 (0.33 to 0.48)
Statistical analysis
  • Part C-Pivotal: Placebo vs Part C-Pivotal: BIIB067 100 mg · ANCOVA · p = < 0.0001 (The analysis was based on ANCOVA model with natural log transformed data. The model included covariates for the corresponding baseline value i.e. log value, baseline disease duration since symptom onset, and use of riluzole or edaravone.) · Difference in ls geometric mean ratio: 0.33 · 95% CI 0.25 to 0.45P-value for this secondary OM is nominal as statistical significance was not met on the primary OM.
SecondaryPart C: Change From Baseline in Percent Predicted Slow Vital Capacity (SVC) at Week 28

Vital capacity was measured by means of an SVC test, administered in the upright position.

Time frame:
Baseline, Week 28 (Day 197)
Reported as:
Least squares mean · percent predicted
Part C: Change From Baseline in Percent Predicted Slow Vital Capacity (SVC) at Week 28
percent predictedPart C-Pivotal: PlaceboPart C-Pivotal: BIIB067 100 mg
Part C: Change From Baseline in Percent Predicted Slow Vital Capacity (SVC) at Week 28-22.20 ± 4.771-14.31 ± 3.557
Statistical analysis
  • Part C-Pivotal: Placebo vs Part C-Pivotal: BIIB067 100 mg · Joint rank · p = = 0.3233 (Joint rank p-value was calculated from ANCOVA model which included treatment as fixed effect, adjusts for covariates: Baseline disease duration since symptom onset, baseline ALSFRS-R total score, baseline SVC, and use of riluzole or edaravone.) · Ls mean difference: 7.90 · 95% CI -3.528 to 19.322ANCOVA model included treatment as a fixed effect, adjusts for the covariates: Baseline disease duration since symptom onset, baseline ALSFRS-R total score, baseline SVC, and use of riluzole or edaravone.
SecondaryPart C: Change From Baseline in Handheld Dynamometry (HHD) Megascore as Measured by the HHD Device at Week 28

Quantitative muscle strength was evaluated using HHD, which tests isometric strength of multiple muscles using standard participant positioning. Sixteen muscle groups were evaluated in both upper and lower extremities. The muscle strength values were normalized to Z scores as (post-baseline measurements - mean)/SD and averaged to provide HHD overall megascore. The overall megascore was created by averaging all eight bilateral measurement Z scores, if no more than 10 (≤ 10) measures are missing. A negative change from baseline indicated decreased muscle strength.

Time frame:
Baseline, Week 28 (Day 197)
Reported as:
Least squares mean · score on a scale
Part C: Change From Baseline in Handheld Dynamometry (HHD) Megascore as Measured by the HHD Device at Week 28
score on a scalePart C-Pivotal: PlaceboPart C-Pivotal: BIIB067 100 mg
Part C: Change From Baseline in Handheld Dynamometry (HHD) Megascore as Measured by the HHD Device at Week 28-0.37 ± 0.096-0.34 ± 0.073
Statistical analysis
  • Part C-Pivotal: Placebo vs Part C-Pivotal: BIIB067 100 mg · ANCOVA · p = = 0.8390 (ANCOVA model included treatment as fixed effect and adjusts for following covariates: Baseline disease duration since symptom onset, baseline HHD overall megascore, and use of riluzole/edaravone. Missing data were handled using multiple imputation.) · Ls mean difference: 0.02 · 95% CI -0.207 to 0.255P-value for this secondary OM is nominal as statistical significance was not met on the primary OM.
SecondaryPart C: Time to Death or Permanent Ventilation

Time to Death or Permanent Ventilation is defined as the time to the earliest occurrence of one of the following events that were adjudicated by an independent committee: Death; Permanent ventilation (≥22 hours of mechanical ventilation \[invasive or noninvasive\] per day for ≥21 consecutive days).

Time frame:
Baseline up to Week 28 (Day 197)
Reported as:
Median · days
Part C: Time to Death or Permanent Ventilation
daysPart C-Pivotal: PlaceboPart C-Pivotal: BIIB067 100 mg
Part C: Time to Death or Permanent VentilationNA (NA to NA)NA (NA to NA)
SecondaryPart C: Time to Death
Time frame:
Baseline up to Week 28 (Day 197)
Reported as:
Median · days
Part C: Time to Death
daysPart C-Pivotal: PlaceboPart C-Pivotal: BIIB067 100 mg
Part C: Time to DeathNA (NA to NA)NA (NA to NA)
SecondaryPart C: Number of Participants Experiencing AEs and SAEs

An AE is any untoward medical occurrence in a participant or clinical investigation participant administered a pharmaceutical product and that does not necessarily have a causal relationship with this treatment. An AE can therefore be any unfavorable and unintended sign (including an abnormal laboratory finding), symptom, or disease temporally associated with the use of a medicinal (investigational) product, whether or not related to the medicinal (investigational) product. A SAE is any untoward medical occurrence that at any dose results in death, life-threatening event, requires inpatient hospitalization, significant disability/incapacity or congenital anomaly.

Time frame:
First dose up to Day 236
Reported as:
Count of participants · Participants
Part C: Number of Participants Experiencing AEs and SAEs
ParticipantsPart C-Pivotal: PlaceboPart C-Pivotal: BIIB067 100 mg
AEs3469
SAEs513

Adverse events

Collected over Part A: First dose up to Day 63; Part B: First dose up to Day 289; Part C: First dose up to Day 236. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Part A-SAD: Combined Placebo0/5 (0%)0/5 (0%)2/5 (40%)
Part A-SAD: Cohort 1: BIIB067 10 mg0/3 (0%)0/3 (0%)2/3 (66.7%)
Part A-SAD: Cohort 2: BIIB067 20 mg0/3 (0%)0/3 (0%)3/3 (100%)
Part A-SAD: Cohort 3: BIIB067 40 mg0/3 (0%)0/3 (0%)3/3 (100%)
Part A-SAD: Cohort 4: BIIB067 60 mg0/6 (0%)0/6 (0%)6/6 (100%)
Part B-MAD: Combined Placebo1/12 (8.3%)2/12 (16.7%)11/12 (91.7%)
Part B-MAD: Cohort 5: BIIB067 20 mg1/10 (10%)2/10 (20%)10/10 (100%)
Part B-MAD: Cohort 6: BIIB067 40 mg0/9 (0%)1/9 (11.1%)9/9 (100%)
Part B-MAD: Cohort 7: BIIB067 60 mg1/9 (11.1%)2/9 (22.2%)9/9 (100%)
Part B-MAD: Cohort 8: BIIB067 100 mg0/10 (0%)0/10 (0%)10/10 (100%)
Part C-Pivotal: Placebo0/36 (0%)5/36 (13.9%)34/36 (94.4%)
Part C-Pivotal: BIIB067 100 mg1/72 (1.4%)13/72 (18.1%)68/72 (94.4%)
Most frequent serious events
Showing 10 of 22
Most frequent serious events
EventPart A-SAD: Combined PlaceboPart A-SAD: Cohort 1: BIIB067 10 mgPart A-SAD: Cohort 2: BIIB067 20 mgPart A-SAD: Cohort 3: BIIB067 40 mgPart A-SAD: Cohort 4: BIIB067 60 mgPart B-MAD: Combined PlaceboPart B-MAD: Cohort 5: BIIB067 20 mgPart B-MAD: Cohort 6: BIIB067 40 mgPart B-MAD: Cohort 7: BIIB067 60 mgPart B-MAD: Cohort 8: BIIB067 100 mgPart C-Pivotal: PlaceboPart C-Pivotal: BIIB067 100 mg
Respiratory failureRespiratory, thoracic and mediastinal disorders0/50/30/30/30/61/120/101/91/90/100/361/72
Csf protein increasedInvestigations0/50/30/30/30/60/120/100/91/90/100/360/72
Csf white blood cell count increasedInvestigations0/50/30/30/30/60/120/100/91/90/100/360/72
Cardiac failure congestiveCardiac disorders0/50/30/30/30/60/121/100/90/90/100/361/72
DyspnoeaRespiratory, thoracic and mediastinal disorders0/50/30/30/30/60/121/100/90/90/102/360/72
Acute respiratory failureRespiratory, thoracic and mediastinal disorders0/50/30/30/30/61/120/100/90/90/100/361/72
Pulmonary embolismRespiratory, thoracic and mediastinal disorders0/50/30/30/30/60/120/100/90/90/101/363/72
DehydrationMetabolism and nutrition disorders0/50/30/30/30/60/120/100/90/90/101/360/72
AtelectasisRespiratory, thoracic and mediastinal disorders0/50/30/30/30/60/120/100/90/90/101/360/72
Pneumonia aspirationRespiratory, thoracic and mediastinal disorders0/50/30/30/30/60/120/100/90/90/100/362/72
Most frequent other events
Showing 10 of 149
Most frequent other events
EventPart A-SAD: Combined PlaceboPart A-SAD: Cohort 1: BIIB067 10 mgPart A-SAD: Cohort 2: BIIB067 20 mgPart A-SAD: Cohort 3: BIIB067 40 mgPart A-SAD: Cohort 4: BIIB067 60 mgPart B-MAD: Combined PlaceboPart B-MAD: Cohort 5: BIIB067 20 mgPart B-MAD: Cohort 6: BIIB067 40 mgPart B-MAD: Cohort 7: BIIB067 60 mgPart B-MAD: Cohort 8: BIIB067 100 mgPart C-Pivotal: PlaceboPart C-Pivotal: BIIB067 100 mg
Procedural painInjury, poisoning and procedural complications1/50/31/30/33/65/124/101/94/97/1021/3641/72
HeadacheNervous system disorders0/50/32/31/31/67/124/102/94/96/1016/3633/72
FallInjury, poisoning and procedural complications0/50/30/30/30/63/123/103/92/95/1015/3617/72
Back painMusculoskeletal and connective tissue disorders0/50/30/30/32/60/121/101/91/95/102/3615/72
Upper respiratory tract infectionInfections and infestations0/50/30/30/30/60/124/100/92/90/102/365/72
Post lumbar puncture syndromeInjury, poisoning and procedural complications1/50/30/30/30/63/124/103/93/93/1011/3613/72
Abdominal pain lowerGastrointestinal disorders0/50/30/31/30/60/120/100/90/90/100/360/72
Faeces discolouredGastrointestinal disorders0/50/30/31/30/60/120/100/90/90/100/361/72
Infusion site swellingGeneral disorders0/51/30/30/30/60/120/100/90/90/100/360/72
PyrexiaGeneral disorders0/50/30/31/30/60/120/100/91/91/101/363/72

Baseline characteristics

Intention-to-Treat (ITT) populations for parts A, B, and C included all randomized participants who received at least 1 dose or a part of 1 dose of study treatment (BIIB067 or placebo) in Parts A, B, and C respectively. The demographics data reported for Part B arm groups included only the unique participants who were enrolled directly into Part B of the study.

Age, Continuous
Age, Continuous(years)Part A-SAD: Combined PlaceboPart A-SAD: Cohort 1: BIIB067 10 mgPart A-SAD: Cohort 2: BIIB067 20 mgPart A-SAD: Cohort 3: BIIB067 40 mgPart A-SAD: Cohort 4: BIIB067 60 mgPart B-MAD: Combined PlaceboPart B-MAD: Cohort 5: BIIB067 20 mgPart B-MAD: Cohort 6: BIIB067 40 mgPart B-MAD: Cohort 7: BIIB067 60 mgPart B-MAD: Cohort 8: BIIB067 100 mgPart C-Pivotal: PlaceboPart C-Pivotal: BIIB067 100 mgTotal
Mean58.4 ± 9.2950.3 ± 7.6455.3 ± 17.6249.0 ± 3.6145.0 ± 12.8249.2 ± 11.0442.1 ± 11.1957.5 ± 11.7545.6 ± 10.7148.9 ± 10.8051.2 ± 11.5748.1 ± 12.6449.2 ± 12.02
Sex: Female, Male
Sex: Female, Male(Participants)Part A-SAD: Combined PlaceboPart A-SAD: Cohort 1: BIIB067 10 mgPart A-SAD: Cohort 2: BIIB067 20 mgPart A-SAD: Cohort 3: BIIB067 40 mgPart A-SAD: Cohort 4: BIIB067 60 mgPart B-MAD: Combined PlaceboPart B-MAD: Cohort 5: BIIB067 20 mgPart B-MAD: Cohort 6: BIIB067 40 mgPart B-MAD: Cohort 7: BIIB067 60 mgPart B-MAD: Cohort 8: BIIB067 100 mgPart C-Pivotal: PlaceboPart C-Pivotal: BIIB067 100 mgTotal
Female2301453536172978
Male3032276364194398
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)Part A-SAD: Combined PlaceboPart A-SAD: Cohort 1: BIIB067 10 mgPart A-SAD: Cohort 2: BIIB067 20 mgPart A-SAD: Cohort 3: BIIB067 40 mgPart A-SAD: Cohort 4: BIIB067 60 mgPart B-MAD: Combined PlaceboPart B-MAD: Cohort 5: BIIB067 20 mgPart B-MAD: Cohort 6: BIIB067 40 mgPart B-MAD: Cohort 7: BIIB067 60 mgPart B-MAD: Cohort 8: BIIB067 100 mgPart C-Pivotal: PlaceboPart C-Pivotal: BIIB067 100 mgTotal
Hispanic or Latino0000000000145
Not Hispanic or Latino43315945472847120
Unknown or Not Reported100213535372151
Race/Ethnicity, Customized
Race/Ethnicity, Customized(Participants)Part A-SAD: Combined PlaceboPart A-SAD: Cohort 1: BIIB067 10 mgPart A-SAD: Cohort 2: BIIB067 20 mgPart A-SAD: Cohort 3: BIIB067 40 mgPart A-SAD: Cohort 4: BIIB067 60 mgPart B-MAD: Combined PlaceboPart B-MAD: Cohort 5: BIIB067 20 mgPart B-MAD: Cohort 6: BIIB067 40 mgPart B-MAD: Cohort 7: BIIB067 60 mgPart B-MAD: Cohort 8: BIIB067 100 mgPart C-Pivotal: PlaceboPart C-Pivotal: BIIB067 100 mgTotal
Race — Asian00000001004510
Race — Black or African American0000000000011
Race — Native Hawaiian or Other Pacific Islander0000010000001
Race — White43315744472544111
Race — Not Reported100213535372151
Race — Other0000010000012
Amyotrophic Lateral Sclerosis Functional Rating Scale-Revised (ALSFRS-R)
Amyotrophic Lateral Sclerosis Functional Rating Scale-Revised (ALSFRS-R)(score on a scale)Part A-SAD: Combined PlaceboPart A-SAD: Cohort 1: BIIB067 10 mgPart A-SAD: Cohort 2: BIIB067 20 mgPart A-SAD: Cohort 3: BIIB067 40 mgPart A-SAD: Cohort 4: BIIB067 60 mgPart B-MAD: Combined PlaceboPart B-MAD: Cohort 5: BIIB067 20 mgPart B-MAD: Cohort 6: BIIB067 40 mgPart B-MAD: Cohort 7: BIIB067 60 mgPart B-MAD: Cohort 8: BIIB067 100 mgPart C-Pivotal: PlaceboPart C-Pivotal: BIIB067 100 mgTotal
Mean——————————35.4 ± 5.6636.0 ± 6.4035.78 ± 6.109
Cerebrospinal Fluid (CSF) Levels of Total SOD1 Protein Concentration
Cerebrospinal Fluid (CSF) Levels of Total SOD1 Protein Concentration(nanograms per milliliter (ng/mL))Part A-SAD: Combined PlaceboPart A-SAD: Cohort 1: BIIB067 10 mgPart A-SAD: Cohort 2: BIIB067 20 mgPart A-SAD: Cohort 3: BIIB067 40 mgPart A-SAD: Cohort 4: BIIB067 60 mgPart B-MAD: Combined PlaceboPart B-MAD: Cohort 5: BIIB067 20 mgPart B-MAD: Cohort 6: BIIB067 40 mgPart B-MAD: Cohort 7: BIIB067 60 mgPart B-MAD: Cohort 8: BIIB067 100 mgPart C-Pivotal: PlaceboPart C-Pivotal: BIIB067 100 mgTotal
Geometric mean—————70.40 (57.2 to 87.9)102.00 (102.00 to 102.00)125.00 (125.00 to 125.00)82.80 (82.8 to 82.8)135.86 (92.5 to 199.0)107.07 (60.0 to 322.0)103.32 (38.8 to 282.0)104.64 (38.8 to 322.0)
Percentage Predicted Slow Vital Capacity (SVC)
Percentage Predicted Slow Vital Capacity (SVC)(percent predicted)Part A-SAD: Combined PlaceboPart A-SAD: Cohort 1: BIIB067 10 mgPart A-SAD: Cohort 2: BIIB067 20 mgPart A-SAD: Cohort 3: BIIB067 40 mgPart A-SAD: Cohort 4: BIIB067 60 mgPart B-MAD: Combined PlaceboPart B-MAD: Cohort 5: BIIB067 20 mgPart B-MAD: Cohort 6: BIIB067 40 mgPart B-MAD: Cohort 7: BIIB067 60 mgPart B-MAD: Cohort 8: BIIB067 100 mgPart C-Pivotal: PlaceboPart C-Pivotal: BIIB067 100 mgTotal
Mean——————————83.7 ± 17.8780.3 ± 14.2281.50 ± 15.533
Handheld Dynamometry (HHD) Megascore as Measured by the HHD Device
Handheld Dynamometry (HHD) Megascore as Measured by the HHD Device(score on a scale)Part A-SAD: Combined PlaceboPart A-SAD: Cohort 1: BIIB067 10 mgPart A-SAD: Cohort 2: BIIB067 20 mgPart A-SAD: Cohort 3: BIIB067 40 mgPart A-SAD: Cohort 4: BIIB067 60 mgPart B-MAD: Combined PlaceboPart B-MAD: Cohort 5: BIIB067 20 mgPart B-MAD: Cohort 6: BIIB067 40 mgPart B-MAD: Cohort 7: BIIB067 60 mgPart B-MAD: Cohort 8: BIIB067 100 mgPart C-Pivotal: PlaceboPart C-Pivotal: BIIB067 100 mgTotal
Mean——————————0.0 ± 0.600.0 ± 0.67-0.007 ± 0.6396

1 further baseline measures are reported on the registry.

08

Study locations

40 sites
  • Barrow Neurological Institute
    Phoenix, Arizona 85013, United States
  • University of California San Diego Medical Center
    La Jolla, California 92093, United States
  • California Pacific Medical Center
    San Francisco, California 94115, United States
  • Mayo Clinic in Florida
    Jacksonville, Florida 32224, United States
  • University of Miami School of Medicine
    Miami, Florida 33136, United States
  • Bioclinica Research
    Orlando, Florida 32806, United States
  • Emory University Hospital
    Atlanta, Georgia 30322, United States
  • Northwestern University Feinberg School of Medicine
    Chicago, Illinois 60611, United States
  • Johns Hopkins University
    Baltimore, Maryland 21287, United States
  • Massachusetts General Hospital
    Boston, Massachusetts 02114, United States
  • Henry Ford Hospital
    Detroit, Michigan 48202, United States
  • Mayo Clinic - Rochester
    Rochester, Minnesota 55905, United States
  • Washington University School of Medicine
    Saint Louis, Missouri 63110, United States
  • Neurology Associates, P.C.
    Lincoln, Nebraska 68506, United States
  • Columbia University Medical Center
    New York, New York 10032, United States
  • The Cleveland Clinic Foundation
    Cleveland, Ohio 44106, United States
  • Providence ALS Center
    Portland, Oregon 97213, United States
  • University of Pennsylvania
    Philadelphia, Pennsylvania 19104, United States
  • New Orleans Center for Clinical Research/Volunteer Research Group, an AMR Company
    Knoxville, Tennessee 37920, United States
  • Methodist Neurological Institute
    Houston, Texas 77030, United States
  • Westmead Hospital
    Westmead, New South Wales 2145, Australia
  • UZ Leuven
    Leuven, 3000, Belgium
  • University of Calgary - Health Sciences Centre
    Calgary, Alberta T2N 1N4, Canada
  • Research Site
    Edmonton, Alberta T6G 2G3, Canada
  • Sunnybrook Health Sciences Centre
    Toronto, Ontario M4N 3M5, Canada
  • Montreal Neurological Institute
    Montreal, Quebec H3A 2B4, Canada
  • Bispebjerg Hospital
    Copenhagen, 2400, Denmark
  • Hopital Pitie Salpetriere
    Paris, 75651, France
  • University of Ulm
    Ulm, Baden Wuerttemberg 89081, Germany
  • ALS Center - Dept. of Neuroscience "Rita Levi Montalcini", University of Turin
    Torino, 10126, Italy
  • The University of Tokyo Hospital
    Bunkyo-Ku, Japan
  • Research Site
    Fukuoka-shi, Japan
  • Research Site
    Kagoshima City, Japan
  • Research Site
    Shinjuku-ku, Japan
  • Research Site
    Suita-Shi, Japan
  • Research Site
    Yangsan-si, Gyeongsangnam-do 50612, Korea, Republic of
  • Research Site
    Seoul, 04763, Korea, Republic of
  • Research Site
    Warszawa, 01684, Poland
  • Research Site
    London, Greater London SE5 9RS, United Kingdom
  • Research Site
    Sheffield, South Yorkshire S10 2HQ, United Kingdom
09

References and documents

Publications

  • Miller TM, Cudkowicz ME, Genge A, Shaw PJ, Sobue G, Bucelli RC, Chio A, Van Damme P, Ludolph AC, Glass JD, Andrews JA, Babu S, Benatar M, McDermott CJ, Cochrane T, Chary S, Chew S, Zhu H, Wu F, Nestorov I, Graham D, Sun P, McNeill M, Fanning L, Ferguson TA, Fradette S; VALOR and OLE Working Group. Trial of Antisense Oligonucleotide Tofersen for SOD1 ALS. N Engl J Med. 2022 Sep 22;387(12):1099-1110. doi: 10.1056/NEJMoa2204705. PubMed 36129998 ↗
  • Miller T, Cudkowicz M, Shaw PJ, Andersen PM, Atassi N, Bucelli RC, Genge A, Glass J, Ladha S, Ludolph AL, Maragakis NJ, McDermott CJ, Pestronk A, Ravits J, Salachas F, Trudell R, Van Damme P, Zinman L, Bennett CF, Lane R, Sandrock A, Runz H, Graham D, Houshyar H, McCampbell A, Nestorov I, Chang I, McNeill M, Fanning L, Fradette S, Ferguson TA. Phase 1-2 Trial of Antisense Oligonucleotide Tofersen for SOD1 ALS. N Engl J Med. 2020 Jul 9;383(2):109-119. doi: 10.1056/NEJMoa2003715. PubMed 32640130 ↗

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: Yes — In accordance with Biogen's Clinical Trial Transparency and Data Sharing Policy on http://clinicalresearch.biogen.com/

Data sharing details ↗ · vivli.org

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Jan 2016 to primary completion in Jul 2021, 65 months.

Results were first posted in Jul 2023, 2 years after primary completion. A results delay was requested in Jul 2022.

Of 24 phase 3 interventional studies under Amyotrophic Lateral Sclerosis, half reached primary completion within 28 months of starting (the median), counting those still running; a quarter within 25 and three quarters within 60. This study's 65 months is above that.

How these figures are worked out, and which studies are left out of them.

Registered
Nov 24, 2015
First posted
Dec 8, 2015
StartActual
Jan 20, 2016
Primary completionActual
Jul 16, 2021
CompletionActual
Jul 16, 2021
Results delay requested
Jul 15, 2022
Results first posted
Jul 28, 2023
Last update
Jul 28, 2023
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jul 28, 2023, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT02623699
Lead sponsor
Biogen
Responsible party
Sponsor
First posted
Dec 8, 2015
Start date
Jan 20, 2016
Primary completion
Jul 16, 2021
Completion
Jul 16, 2021
Results posted
Jul 28, 2023
Last update
Jul 28, 2023

Study contacts

Medical Director
study director · Biogen

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jul 2023. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Tofersen

Start the discussion